|Table of Contents|

The mechanism of up-regulating miR-93-5p expression in colon cancer mesenchymal stem cell inhibit colon cancer cell proliferation and promote apoptosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 05
Page:
723-727
Research Field:
Publishing date:

Info

Title:
The mechanism of up-regulating miR-93-5p expression in colon cancer mesenchymal stem cell inhibit colon cancer cell proliferation and promote apoptosis
Author(s):
YAN Xiaofei1; TIAN Jiaxun2; QIAO Yun1; WANG Nan3; YANG Shihua1; ZHANG Jifu1; MA Shiyang1; GAO Xiaozhuo4; SHI Gang1
1.Department of Colorectal Surgery；2.Department of Medical Laboratory;3.Department of Radiotherapy;4.Department of Pathology,Cancer Hospital of China Medical University,Liaoning Cancer Hospital ﹠Institute,Liaoning Shenyang 110042,China.
Keywords:
miR-93-5p; colon cancer; mesenchymal stem cell; PD-L1
PACS:
R735.35
DOI:
10.3969/j.issn.1672-4992.2021.05.002
Abstract:
Objective:To observe the effect of up-regulating miR-93-5p expression in colon cancer mesenchymal stem cell(CCMSC) on proliferation,apoptosis and discuss the mechanisms.Methods:CCMSC and colon mesenchymal stem cell(CMSC) were extracted from colon cancer or colon tissues by tissue adhere cell culture assay.miR-93-5p and PD-L1 expression were detected.CCMSC was transfected with miR-93-5p mimics,CCK8 and flow cytometry assay were used to detect proliferation or apoptosis.Results:miR-93-5p in colon cancer cells were lower than in normal colon epithelial cells(P＜0.001),PD-L1 mRNA and PD-L1 protein in colon cancer cells were higher than in normal colon epithelial cells（P＜0.001,P＜0.001）.miR-93-5p in CCMSC group was lower than in CMSC（P＜0.001）.Compared with SW480 cell,survival rate of SW480 was increased once interfered with CCMSC（P＜0.001），apoptosis rate was decreased（P＜0.05）.Compared with SW480 or CCMSC/SW480，the survival rate of miR-93-5p mimics CCMSC/SW480 was decreased（P＜0.01，P＜0.001），and the apoptosis rate was increased（P＜0.05，P＜0.01）.Conclusion:Up-regulating miR-93-5p expression suppresses CCMSC induced colon cancer cell proliferation,promotes apoptosis.

References:

[1] JEON Y,PARK EJ,LIM JH,et al.Clinical outcomes of complete cytoreduction with concurrent liver resection followed by hyperthermic intraperitoneal chemotherapy for synchronous peritoneal and liver metastatic colorectal cancer ［J］.World Journal of Surgical Oncology,2019,17(1):214.
[2] CHEN HL,LI JJ,JIANG F,et al.MicroRNA-4461 derived from bone marrow mesenchymal stem cell exosomes inhibits tumorigenesis by downregulating COPB2 expression in colorectal cancer ［J］.Biosci Biotechnol Biochem,2020,84(2):338-346.
[3] NOZAWA H,SONODA H,ISHII H,et al.Postoperative chemotherapy is associated with prognosis of stage Ⅳ colorectal cancer treated with preoperative chemotherapy/chemoradiotherapy and curative resection ［J］.Int J Colorectal Dis,2020,35(1):177-180.
[4] ZHANG C,TAN Y,XU H.Does adjuvant chemotherapy improve the prognosis of patients after resection of pulmonary metastasis from colorectal cancer? A systematic review and meta-analysis ［J］.Int J Colorectal Dis,2019,34(10):1661-1671.
[5] NOZAWA H,TAKIYAMA H,HASEGAWA K,et al.Adjuvant chemotherapy improves prognosis of resectable stage Ⅳ colorectal cancer:a comparative study using inverse probability of treatment weighting ［J］.Ther Adv Med Oncol,2019,11(1):7588-7598.
[6] FRANCOIS S,USUNIER B,FORGUE-LAFITTE ME,et al.Mesenchymal stem cell administration attenuates colon cancer progression by modulating the immune component within the colorectal tumor microenvironment［J］.Stem Cells Transl Med,2019,8(3):285-300.
[7] FU Y,LIN L,XIA L.MiR-107 function as a tumor suppressor gene in colorectal cancer by targeting transferrin receptor 1 ［J］.Cellular & Molecular Biology Letters,2019,24(31)：45-51.
[8] ZHANG S,JIN J,TIAN X,et al.hsa-miR-29c-3p regulates biological function of colorectal cancer by targeting SPARC ［J］.Oncotarget,2017,8(61):104508-104524.
[9] WANG XJ,XIA M,BI WP.Decreased expression of miR-874 and its tumor suppressive function in human colorectal cancer ［J］.Genetics and Molecular Research,2016,15(2):67-74.
[10] BRUTTEL VS,WISCHHUSEN J.Cancer stem cell immunology:key to understanding tumorigenesis and tumor immune escape［J］.Front Immunol,2014,5(3):60-71.
[11] JIANG C,CAO S,LI N,et al.PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer ［J］.Cancer Cell Int,2019,19(2):33.
[12] LI RP,LI YW,GUO YZ.PD-1 and PD-L1 expression on the prognosis of ovarian cancer ［J］.J Biol Regul Homeost Agents,2019,33(4):1161-1166.
[13] WANG Z,ZHANG B,ZHANG C,et al.Effect of region on the outcome of patients receiving PD-1/PD-L1 inhibitors for advanced cancer ［J］.Int Immunopharmacol,2019,74(10):57-69.
[14] RAHMANI KUKIA N,ALIPANAH-MOGHADAM R,DELIREZH N,et al.Mesenchymal stromal stem cell-derived microvesicles enhance tumor lysate pulsed dendritic cell stimulated autologous T lymphocyte cytotoxicity［J］.Asian Pac J Cancer Prev,2018,19(7):1895-1902.
[15] BATOROV EV,SHEVELA EY,TIKHONOVA MA,et al.Mesenchymal stromal cells improve early lymphocyte recovery and T cell reconstitution after autologous hematopoietic stem cell transplantation in patients with malignant lymphomas［J］.Cell Immunol,2015,297(2):80-86.
[16] LIN S,HUANG G,CHENG L,et al.Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy［J］.Mabs,2018,10(8):1301-1311.
[17] KHALIFE E,KHODADADI A,TALAEIZADEH A,et al.Overexpression of regulatory T cell-related markers（FOXP3,CTLA-4 and GITR) by peripheral blood mononuclear cells from patients with breast cancer［J］.Asian Pac J Cancer Prev,2018,19(11):3019-3025.
[18] RUIZ DE GALARRETA M,BRESNAHAN E,MOLINA-SANCHEZ P,et al.Beta-Catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma［J］.Cancer Discovery,2019,9(8):1124-1141.
[19] YUAN L,YE J,FAN D.The B7-H4 gene induces immune escape partly via upregulating the PD-1/Stat3 pathway in non-small cell lung cancer［J］.Human Immunology,2020,81(5):254-261.
[20] ZHOU TC,SANKIN AI,PORCELLI SA,et al.A review of the PD-1/PD-L1 checkpoint in bladder cancer:From mediator of immune escape to target for treatment［J］.Urologic Oncology,2017,35(1):14-20.

Memo

Memo:
辽宁省自然科学基金（编号：2019-MS-211，2020-ZLLH-42）
Last Update: 2021-01-29